UNISOLV has commissioned a new manufacturing line dedicated to active pharmaceutical ingredient production, increasing annual capacity by approximately 40%. The expansion supports growing demand from generic drug manufacturers across North America and Europe, while maintaining the strict quality controls our partners depend on.
The new facility incorporates advanced process monitoring and automated quality checkpoints, reinforcing UNISOLV quality commitments.
